EcoDrugPlus

B2 Bradykinin Receptor-Like

Ensembl ID : ENSBSLG00000023905
Gene Symbol: LOC114848731
2 Cross references
241 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSBSLG00000023910
Gene Symbol: BCL2L1
3 Cross references
216 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSBSLG00000022982
Gene Symbol: BCR
3 Cross references
209 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSBSLG00000002567
Gene Symbol: LOC114866706
3 Cross references
210 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSBSLG00000025400
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSBSLG00000018613
Gene Symbol: LOC114854650
2 Cross references
194 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSBSLG00000022784
Gene Symbol: LOC114845017
2 Cross references
190 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSBSLG00000024556
Gene Symbol: LOC114847798
2 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSBSLG00000018918
Gene Symbol: CXCR4
3 Cross references
216 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSBSLG00000014188
Gene Symbol: LOC114843566
2 Cross references
394 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSBSLG00000009227
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

D(1) Dopamine Receptor-Like

Ensembl ID : ENSBSLG00000024507
Gene Symbol: LOC114864750
2 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).